MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update

Rhea-AI Summary

MiNK Therapeutics, a clinical-stage biopharmaceutical company focused on iNKT cell therapies for cancer and immune-mediated diseases, will announce its Q1 2022 financial results and business update on May 10, 2022, before market opens. The disclosure will be made via press release and available on the company's investor website. MiNK is advancing a pipeline of native and next-generation engineered iNKT therapies, aiming for scalable off-the-shelf delivery.

Positive

• Company advancing a pipeline of both native and next-generation engineered iNKT programs.
• Focus on scalable and reproducible manufacturing for off-the-shelf delivery.

Negative

• None.

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced it will release its first quarter 2022 financial results and business update before the market opens on Tuesday, May 10, 2022.

The financial report and an update on business progress will be released through a press release on online distribution networks and available on the investor section of the company’s website.

About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.

Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

FAQ

When will MiNK Therapeutics announce Q1 2022 financial results?

MiNK Therapeutics will announce its Q1 2022 financial results on May 10, 2022.

What type of therapies does MiNK Therapeutics focus on?

MiNK Therapeutics focuses on allogeneic iNKT cell therapies for cancer and immune-mediated diseases.

How can I access the financial report of MiNK Therapeutics?

The financial report will be available through a press release and on the investor section of MiNK Therapeutics' website.